Muhammad Asad, Resident Radiation Oncology at Institute of Nuclear Medicine And Oncology Lahore INMOL, shared a post on LinkedIn:
“Master CDK4/6 inhibitors in under 12 minutes
A concise, exam-focused breakdown of one of the most important drug classes in modern oncology — simplified for quick learning and clinical recall.
In this video, I cover:
- What are cyclins and cyclin-CDK complexes?
- Background of CDK Inhibtors
- Mechanism of action (G1 → S phase arrest)
- Key differences: Palbociclib vs Ribociclib vs Abemaciclib
- Toxicities & clinical pearls
- Landmark trials investigating these agents
Must-know trials:
Metastatic setting (HR+/HER2−):
- PALOMA-2 (Palbociclib)
- MONALEESA-2, MONALEESA-7 (Ribociclib)
- MONARCH-3 (Abemaciclib)
Adjuvant setting:
- MONARCH-E (Abemaciclib)
- NATALEE (Ribociclib)
These trials have redefined the standard of care by demonstrating significant improvements in progression-free survival — and in several studies, overall survival — when CDK4/6 inhibitors are combined with endocrine therapy.
Ideal for residents, oncology trainees, and anyone preparing for FRCR or board exams.”
Other articles featuring Muhammad Asad on OncoDaily.